
Oculis Holding AG
NASDAQ:OCS
Overview | Financials
Company Name | Oculis Holding AG |
Symbol | OCS |
Currency | USD |
Price | 18.58 |
Market Cap | 891,840,000 |
Dividend Yield | 0% |
52-week-range | 10.79 - 23.08 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Riad Sherif M.B.A., M.D. |
Website | https://oculis.com |
An error occurred while fetching data.
About Oculis Holding AG
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD